Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment
Aim Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with fi...
Gespeichert in:
Veröffentlicht in: | Asia-Pacific journal of clinical oncology 2017-10, Vol.13 (5), p.e189-e194 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e194 |
---|---|
container_issue | 5 |
container_start_page | e189 |
container_title | Asia-Pacific journal of clinical oncology |
container_volume | 13 |
creator | Lin, Gui‐Nan Peng, Jie‐Wen Liu, Pan‐Pan Liu, Dong‐Ying Xiao, Jian‐jun Chen, Xiao‐Qin |
description | Aim
Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed.
Methods
81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated.
Results
Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P |
doi_str_mv | 10.1111/ajco.12273 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826611768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1957021013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</originalsourceid><addsrcrecordid>eNp9kUluFDEUhi0EIgNsOACyxAZF6uChXMMyaoVJkbKBteVyPafdctmF7eqodxyBs3AkToKLClmwwAtP79P3bP0IvaLkkpbxTu11uKSMNfwJOqVNxTeNqPnTx70QJ-gspT0hvGMdfY5OmOCiYy05RT-vHRxUhgF7mHMM0866X99_5FAmdxynXdDHDDiqbAOeIgxW54SnECIOc9ZhBGw9nkoZfCnc27zDajgorxdl8EWTRuUWpwbnsJv9HdZLOeIIGuzBlgtjY8pLR-sB34Gx2Xrb49IEogvrIUdQeSxdXqBnRrkELx_Wc_T1_fWX7cfNze2HT9urm43mouEbw3tjYIC-6hTpDataQxvFFRlAmKHVUPGW8EForVjNGiNYxTQhmipgbd0Zfo7ert4phm8zpCxHm5ZPKA9hTpK2rK4pbeq2oG_-Qfdhjr68TtJONIRRQnmhLlZKx5BSBCOnaEcVj5ISuSQplyTlnyQL_PpBOfcjDI_o3-gKQFfg3jo4_kclrz5vb1fpb4oRs0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1957021013</pqid></control><display><type>article</type><title>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lin, Gui‐Nan ; Peng, Jie‐Wen ; Liu, Pan‐Pan ; Liu, Dong‐Ying ; Xiao, Jian‐jun ; Chen, Xiao‐Qin</creator><creatorcontrib>Lin, Gui‐Nan ; Peng, Jie‐Wen ; Liu, Pan‐Pan ; Liu, Dong‐Ying ; Xiao, Jian‐jun ; Chen, Xiao‐Qin</creatorcontrib><description>Aim
Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed.
Methods
81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated.
Results
Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P < 0.001 and 17.20 vs 23.20 months, P < 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression‐free and overall survival in Cox multivariate analysis.
Conclusion
Elevated NLR is likely to be associated with poor outcome in EGFR‐mutated advanced NSCLC patients treated with first‐line EGFR TKIs.</description><identifier>ISSN: 1743-7555</identifier><identifier>EISSN: 1743-7563</identifier><identifier>DOI: 10.1111/ajco.12273</identifier><identifier>PMID: 25359280</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Aged ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Epidermal growth factor ; epidermal growth factor receptor ; Epidermal growth factor receptors ; Erlotinib Hydrochloride - adverse effects ; Erlotinib Hydrochloride - therapeutic use ; Female ; Gefitinib ; Humans ; Lung cancer ; Lung Neoplasms - blood ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Lymphocytes - pathology ; Male ; Medical prognosis ; Metastases ; Multivariate analysis ; Neutrophils ; Neutrophils - pathology ; neutrophil‐to‐lymphocyte ratio ; Non-small cell lung carcinoma ; non‐small‐cell lung cancer ; Patients ; Predictive Value of Tests ; Prognosis ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; Survival Analysis ; Treatment Outcome</subject><ispartof>Asia-Pacific journal of clinical oncology, 2017-10, Vol.13 (5), p.e189-e194</ispartof><rights>2014 Wiley Publishing Asia Pty Ltd</rights><rights>2014 Wiley Publishing Asia Pty Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</citedby><cites>FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajco.12273$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajco.12273$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25359280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Gui‐Nan</creatorcontrib><creatorcontrib>Peng, Jie‐Wen</creatorcontrib><creatorcontrib>Liu, Pan‐Pan</creatorcontrib><creatorcontrib>Liu, Dong‐Ying</creatorcontrib><creatorcontrib>Xiao, Jian‐jun</creatorcontrib><creatorcontrib>Chen, Xiao‐Qin</creatorcontrib><title>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</title><title>Asia-Pacific journal of clinical oncology</title><addtitle>Asia Pac J Clin Oncol</addtitle><description>Aim
Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed.
Methods
81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated.
Results
Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P < 0.001 and 17.20 vs 23.20 months, P < 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression‐free and overall survival in Cox multivariate analysis.
Conclusion
Elevated NLR is likely to be associated with poor outcome in EGFR‐mutated advanced NSCLC patients treated with first‐line EGFR TKIs.</description><subject>Aged</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Epidermal growth factor</subject><subject>epidermal growth factor receptor</subject><subject>Epidermal growth factor receptors</subject><subject>Erlotinib Hydrochloride - adverse effects</subject><subject>Erlotinib Hydrochloride - therapeutic use</subject><subject>Female</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Multivariate analysis</subject><subject>Neutrophils</subject><subject>Neutrophils - pathology</subject><subject>neutrophil‐to‐lymphocyte ratio</subject><subject>Non-small cell lung carcinoma</subject><subject>non‐small‐cell lung cancer</subject><subject>Patients</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1743-7555</issn><issn>1743-7563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUluFDEUhi0EIgNsOACyxAZF6uChXMMyaoVJkbKBteVyPafdctmF7eqodxyBs3AkToKLClmwwAtP79P3bP0IvaLkkpbxTu11uKSMNfwJOqVNxTeNqPnTx70QJ-gspT0hvGMdfY5OmOCiYy05RT-vHRxUhgF7mHMM0866X99_5FAmdxynXdDHDDiqbAOeIgxW54SnECIOc9ZhBGw9nkoZfCnc27zDajgorxdl8EWTRuUWpwbnsJv9HdZLOeIIGuzBlgtjY8pLR-sB34Gx2Xrb49IEogvrIUdQeSxdXqBnRrkELx_Wc_T1_fWX7cfNze2HT9urm43mouEbw3tjYIC-6hTpDataQxvFFRlAmKHVUPGW8EForVjNGiNYxTQhmipgbd0Zfo7ert4phm8zpCxHm5ZPKA9hTpK2rK4pbeq2oG_-Qfdhjr68TtJONIRRQnmhLlZKx5BSBCOnaEcVj5ISuSQplyTlnyQL_PpBOfcjDI_o3-gKQFfg3jo4_kclrz5vb1fpb4oRs0c</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Lin, Gui‐Nan</creator><creator>Peng, Jie‐Wen</creator><creator>Liu, Pan‐Pan</creator><creator>Liu, Dong‐Ying</creator><creator>Xiao, Jian‐jun</creator><creator>Chen, Xiao‐Qin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</title><author>Lin, Gui‐Nan ; Peng, Jie‐Wen ; Liu, Pan‐Pan ; Liu, Dong‐Ying ; Xiao, Jian‐jun ; Chen, Xiao‐Qin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3573-f3bffedeb49a0bf248f17a3a0de5fd8ce43803d5cca2627f5242c00c1ae2869f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Epidermal growth factor</topic><topic>epidermal growth factor receptor</topic><topic>Epidermal growth factor receptors</topic><topic>Erlotinib Hydrochloride - adverse effects</topic><topic>Erlotinib Hydrochloride - therapeutic use</topic><topic>Female</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Multivariate analysis</topic><topic>Neutrophils</topic><topic>Neutrophils - pathology</topic><topic>neutrophil‐to‐lymphocyte ratio</topic><topic>Non-small cell lung carcinoma</topic><topic>non‐small‐cell lung cancer</topic><topic>Patients</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Gui‐Nan</creatorcontrib><creatorcontrib>Peng, Jie‐Wen</creatorcontrib><creatorcontrib>Liu, Pan‐Pan</creatorcontrib><creatorcontrib>Liu, Dong‐Ying</creatorcontrib><creatorcontrib>Xiao, Jian‐jun</creatorcontrib><creatorcontrib>Chen, Xiao‐Qin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Asia-Pacific journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Gui‐Nan</au><au>Peng, Jie‐Wen</au><au>Liu, Pan‐Pan</au><au>Liu, Dong‐Ying</au><au>Xiao, Jian‐jun</au><au>Chen, Xiao‐Qin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment</atitle><jtitle>Asia-Pacific journal of clinical oncology</jtitle><addtitle>Asia Pac J Clin Oncol</addtitle><date>2017-10</date><risdate>2017</risdate><volume>13</volume><issue>5</issue><spage>e189</spage><epage>e194</epage><pages>e189-e194</pages><issn>1743-7555</issn><eissn>1743-7563</eissn><abstract>Aim
Elevated neutrophil‐to‐lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC) patients treated with first‐line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed.
Methods
81 metastatic NSCLC patients harboring EGFR mutation treated with first‐line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated.
Results
Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression‐free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P < 0.001 and 17.20 vs 23.20 months, P < 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression‐free and overall survival in Cox multivariate analysis.
Conclusion
Elevated NLR is likely to be associated with poor outcome in EGFR‐mutated advanced NSCLC patients treated with first‐line EGFR TKIs.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>25359280</pmid><doi>10.1111/ajco.12273</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1743-7555 |
ispartof | Asia-Pacific journal of clinical oncology, 2017-10, Vol.13 (5), p.e189-e194 |
issn | 1743-7555 1743-7563 |
language | eng |
recordid | cdi_proquest_miscellaneous_1826611768 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Aged Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Epidermal growth factor epidermal growth factor receptor Epidermal growth factor receptors Erlotinib Hydrochloride - adverse effects Erlotinib Hydrochloride - therapeutic use Female Gefitinib Humans Lung cancer Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lymphocytes - pathology Male Medical prognosis Metastases Multivariate analysis Neutrophils Neutrophils - pathology neutrophil‐to‐lymphocyte ratio Non-small cell lung carcinoma non‐small‐cell lung cancer Patients Predictive Value of Tests Prognosis Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Quinazolines - adverse effects Quinazolines - therapeutic use Survival Analysis Treatment Outcome |
title | Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T12%3A45%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20neutrophil%E2%80%90to%E2%80%90lymphocyte%20ratio%20predicts%20poor%20outcome%20in%20patients%20with%20advanced%20non%E2%80%90small%E2%80%90cell%20lung%20cancer%20receiving%20first%E2%80%90line%20gefitinib%20or%20erlotinib%20treatment&rft.jtitle=Asia-Pacific%20journal%20of%20clinical%20oncology&rft.au=Lin,%20Gui%E2%80%90Nan&rft.date=2017-10&rft.volume=13&rft.issue=5&rft.spage=e189&rft.epage=e194&rft.pages=e189-e194&rft.issn=1743-7555&rft.eissn=1743-7563&rft_id=info:doi/10.1111/ajco.12273&rft_dat=%3Cproquest_cross%3E1957021013%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1957021013&rft_id=info:pmid/25359280&rfr_iscdi=true |